Danaher Corporation reported strong financial performance with notable growth in the bioprocessing segment and successful new product launches. However, challenges in China and a decline in Life Sciences and equipment revenue were highlighted as areas of concern. Overall, the company is optimistic about overcoming these challenges and maintains a positive outlook for the future.
Company Guidance
In the recent earnings call for Danaher Corporation's third quarter of 2025, the company provided a comprehensive outlook on its financial performance and strategic initiatives. Danaher reported sales of $6.1 billion, reflecting a 3% core revenue growth year-over-year. The gross profit margin stood at 58.2%, while the adjusted operating profit margin increased by 40 basis points to 27.9%. Adjusted diluted net earnings per common share were reported at $1.89, marking a 10% increase from the previous year. Danaher generated $1.4 billion in free cash flow in the third quarter, contributing to a year-to-date free cash flow to net income conversion ratio of 146%. The company deployed approximately $2 billion for the repurchase of 10 million shares, and its Board approved a new share repurchase program for up to 35 million additional shares. Looking ahead, Danaher maintained its adjusted diluted net EPS guidance range of $7.70 to $7.80 for the full year 2025 and expects core revenue growth in the low single-digit percent range for the fourth quarter. Initial guidance for 2026 includes anticipated core revenue growth in the 3% to 6% range, with expected over 100 basis points of adjusted operating profit margin expansion, resulting in high single-digit adjusted earnings per share growth.
Strong Financial Performance
Danaher Corporation delivered third quarter sales of $6.1 billion and a 3% core revenue growth. The adjusted diluted net earnings per common share were up approximately 10% year-over-year at $1.89.
Bioprocessing Business Momentum
The bioprocessing segment saw high single-digit growth in core revenue, driven by robust demand for commercialized therapies at large pharma and CDMO customers.
Successful New Product Launches
Danaher launched several leading-edge products and technologies, including Cytiva's ÄKTA readyflux TFF system 500 and Beckman Coulter's Access and BD-tau assay.
Share Repurchase Program
Danaher deployed approximately $2 billion towards the repurchase of 10 million shares and approved a new program authorizing the purchase of up to 35 million additional shares.
Danaher (DHR) Earnings, Revenues Date & History
The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DHR Earnings-Related Price Changes
Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Oct 21, 2025
$208.39
$220.77
+5.94%
Jul 22, 2025
$187.74
$189.58
+0.98%
Apr 22, 2025
$184.34
$191.43
+3.85%
Jan 29, 2025
$246.63
$222.64
-9.73%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Danaher Corporation (DHR) report earnings?
Danaher Corporation (DHR) is schdueled to report earning on Feb 04, 2026, Before Open (Confirmed).
What is Danaher Corporation (DHR) earnings time?
Danaher Corporation (DHR) earnings time is at Feb 04, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.